471 related articles for article (PubMed ID: 26215636)
1. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.
O'Shea JP; Faisal W; Ruane-O'Hora T; Devine KJ; Kostewicz ES; O'Driscoll CM; Griffin BT
Eur J Pharm Biopharm; 2015 Oct; 96():207-16. PubMed ID: 26215636
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Fei Y; Kostewicz ES; Sheu MT; Dressman JB
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
[TBL] [Abstract][Full Text] [Related]
3. Combining in vitro and in silico methods for better prediction of surfactant effects on the absorption of poorly water soluble drugs-a fenofibrate case example.
Berthelsen R; Sjögren E; Jacobsen J; Kristensen J; Holm R; Abrahamsson B; Müllertz A
Int J Pharm; 2014 Oct; 473(1-2):356-65. PubMed ID: 24997410
[TBL] [Abstract][Full Text] [Related]
4. The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate.
Do TT; Van Speybroeck M; Mols R; Annaert P; Martens J; Van Humbeeck J; Vermant J; Augustijns P; Van den Mooter G
Int J Pharm; 2011 Jul; 414(1-2):118-24. PubMed ID: 21596119
[TBL] [Abstract][Full Text] [Related]
5. IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system.
Buch P; Langguth P; Kataoka M; Yamashita S
J Pharm Sci; 2009 Jun; 98(6):2001-9. PubMed ID: 18855916
[TBL] [Abstract][Full Text] [Related]
6. Design of fenofibrate microemulsion for improved bioavailability.
Hu L; Wu H; Niu F; Yan C; Yang X; Jia Y
Int J Pharm; 2011 Nov; 420(2):251-5. PubMed ID: 21907776
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of oral bioavailability of fenofibrate by solid self-microemulsifying drug delivery systems.
Kim GG; Poudel BK; Marasini N; Lee DW; Hiep TT; Yang KY; Kim JO; Yong CS; Choi HG
Drug Dev Ind Pharm; 2013 Sep; 39(9):1431-8. PubMed ID: 23046292
[TBL] [Abstract][Full Text] [Related]
8. A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate.
Jia Z; Lin P; Xiang Y; Wang X; Wang J; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2011 Sep; 79(1):126-34. PubMed ID: 21658449
[TBL] [Abstract][Full Text] [Related]
9. Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles.
Juenemann D; Jantratid E; Wagner C; Reppas C; Vertzoni M; Dressman JB
Eur J Pharm Biopharm; 2011 Feb; 77(2):257-64. PubMed ID: 21074611
[TBL] [Abstract][Full Text] [Related]
10. Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo.
Linn M; Collnot EM; Djuric D; Hempel K; Fabian E; Kolter K; Lehr CM
Eur J Pharm Sci; 2012 Feb; 45(3):336-43. PubMed ID: 22172603
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evaluation of a self-microemulsifying drug delivery system for the poorly soluble drug fenofibrate.
Cho YD; Park YJ
Arch Pharm Res; 2014 Feb; 37(2):193-203. PubMed ID: 23754165
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of fenofibrate dissolution delivered by a self-microemulsifying drug-delivery system.
Wei JD; Ho HO; Chen CH; Ke WT; Chen ET; Sheu MT
J Pharm Pharmacol; 2010 Dec; 62(12):1685-96. PubMed ID: 21054394
[TBL] [Abstract][Full Text] [Related]
13. Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.
Suys EJA; Chalmers DK; Pouton CW; Porter CJH
Mol Pharm; 2018 Jun; 15(6):2355-2371. PubMed ID: 29659287
[TBL] [Abstract][Full Text] [Related]
14. The in vitro and in vivo evaluation of fenofibrate with a self- microemulsifying formulation.
Xiumin LI; Man GE; Minzi LU; Yinghua J; Dongqin Q
Curr Drug Deliv; 2015; 12(3):308-13. PubMed ID: 26054534
[TBL] [Abstract][Full Text] [Related]
15. Mesoporous silica-based dosage forms improve bioavailability of poorly soluble drugs in pigs: case example fenofibrate.
O'Shea JP; Nagarsekar K; Wieber A; Witt V; Herbert E; O'Driscoll CM; Saal C; Lubda D; Griffin BT; Dressman JB
J Pharm Pharmacol; 2017 Oct; 69(10):1284-1292. PubMed ID: 28631822
[TBL] [Abstract][Full Text] [Related]
16. In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation.
McCarthy CA; Faisal W; O'Shea JP; Murphy C; Ahern RJ; Ryan KB; Griffin BT; Crean AM
J Control Release; 2017 Mar; 250():86-95. PubMed ID: 28132935
[TBL] [Abstract][Full Text] [Related]
17. Novel electrosprayed nanospherules for enhanced aqueous solubility and oral bioavailability of poorly water-soluble fenofibrate.
Yousaf AM; Mustapha O; Kim DW; Kim DS; Kim KS; Jin SG; Yong CS; Youn YS; Oh YK; Kim JO; Choi HG
Int J Nanomedicine; 2016; 11():213-21. PubMed ID: 26834471
[TBL] [Abstract][Full Text] [Related]
18. Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate.
Griffin BT; Kuentz M; Vertzoni M; Kostewicz ES; Fei Y; Faisal W; Stillhart C; O'Driscoll CM; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2014 Apr; 86(3):427-37. PubMed ID: 24184675
[TBL] [Abstract][Full Text] [Related]
19. Effect of magnesium carbonate on the solubility, dissolution and oral bioavailability of fenofibric acid powder as an alkalising solubilizer.
Kim KS; Kim JH; Jin SG; Kim DW; Kim DS; Kim JO; Yong CS; Cho KH; Li DX; Woo JS; Choi HG
Arch Pharm Res; 2016 Apr; 39(4):531-538. PubMed ID: 26992922
[TBL] [Abstract][Full Text] [Related]
20. Kolliphor surfactants affect solubilization and bioavailability of fenofibrate. Studies of in vitro digestion and absorption in rats.
Berthelsen R; Holm R; Jacobsen J; Kristensen J; Abrahamsson B; Müllertz A
Mol Pharm; 2015 Apr; 12(4):1062-71. PubMed ID: 25679417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
